CLN-049

N/A

Report date: 2026/05/22 20:01:29

Base Information

Drug NameCLN-049
Drug Alias Namea humanized bispecific antibody with dual binding specificities for FLT3 and CD3CLN-049
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsAnti-CD3
TargetsTyrosine-protein kinase receptor FLT3T cell surface glycoprotein CD3
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEberhard-Karls Universitaet TuebingenGerman Cancer Research Center (Dkfz)
China Registration ClassN/A

Develop Information

Active CompaniesCullinan Therapeutics Inc
Inactive CompaniesGerman Cancer Research Center (Dkfz)
Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A